AFP is considered to be the gold-standard serum marker for the screening of patients who are at high risk of HCC, as well as for the monitoring of treatment response (10); however, the clinical value of AFP has been questioned due to its low sensitivity and specificity (11). Here, AFP is linked to hepatocellular carcinoma.